TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07216703: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care a

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1023 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,445,132

Rescue Site Savings

+$3,608,220

Unlock Full NCT07216703 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07216703 Rescue Dossier →